Clinical chemistry testing has advanced dramatically in recent years and the market for clinical chemistry analyzers is growing. According to a recent market report from Persistence Market Research, the key factors driving the global demand for these devices are: rising aging population, increasing number of reagent rental agreements, rising number of lifestyle associated disorders, rising per capita income in developing countries, and increased health care awareness. The report also indicates that North America dominates the global clinical analyzer market, followed by Europe. The reasons for the dominance of these regions are:
- Rising prevalence of infectious and non-infectious diseases
- Increased demand for laboratory automation in clinical laboratories
- Expansion in the number of people with health insurance, especially in the U.S.
The market survey predicts that Asia will be the fastest growing market due to factors such as rising health care infrastructure, increasing government initiatives for better health care facilities, and the presence of a large patient population base.
The report contains an in-depth analysis of the drivers, restraints, and challenges shaping the global market for clinical chemistry analyzers. The leading players in this market are Abbott Laboratories, Randox Laboratories Ltd., Thermo Fisher Scientifc Inc., Siemens AG, Danaher Corporation, Mindray Medical International Limited, and ELITechGroup.
Fully automated low, medium, and high volume clinical chemistry analyzers are available as independent units that help labs with the automation process. Leading manufacturers offer systems that are designed to handle a wide range of sample workloads, ranging from small or modest sized benchtop units to very large floor models.
Laboratories use these advanced clinical chemistry systems to perform tests on blood serum, plasma, urine, and cerebrospinal fluid in orders to detect the presence of analytes such as enzymes, substrates, electrolytes, specific proteins, drugs of abuse, and therapeutic drugs. The results of these tests will provide health care providers information about toxicology and organ function, thereby helping in the diagnosis and treatment of various diseases such as cancer, HIV, diabetes, hepatitis, and kidney disorders.
Most manufacturers also provide reagents for the instruments they offer. If only the proprietary reagents from the instrument manufacturer can be used on the analyzer, it is designated a ‘closed system’. If reagents from many vendors can be adapted to an analyzer, it is designated an ‘open system’. For instance, the fully automated Olympus AU400 analyzer is an open system. Other efficient open systems currently available include the Medica EASYRA and Roche Hitachi 717.